PMID- 30905632 OWN - NLM STAT- MEDLINE DCOM- 20191213 LR - 20191217 IS - 1437-7780 (Electronic) IS - 1341-321X (Linking) VI - 25 IP - 7 DP - 2019 Jul TI - Positivity rate of interferon-gamma release assays for estimating the prevalence of latent tuberculosis infection in renal transplant recipients in Japan. PG - 537-542 LID - S1341-321X(19)30061-3 [pii] LID - 10.1016/j.jiac.2019.02.018 [doi] AB - Renal transplant recipients are at increased risk of reactivating latent tuberculosis infection (LTBI) and developing active tuberculosis. QuantiFERON((R))-TB Gold Plus (QFT-Plus) has two TB-specific antigens tubes (TB1 and TB2). TB1 elicits CD4 T-cell response, and TB2 elicits both CD4 and CD8 T-cells responses, with expected increased sensitivity. The aim of this study was to estimate the prevalence of LTBI in renal transplant recipients in Japan. We conducted a cross-sectional study by using two interferon-gamma release assays (IGRAs), QFT-Plus and T-SPOT((R)).TB (TSPOT). One hundred thirty-five recipients were prospectively enrolled. The median age was 49 years (range: 20 to 79). The positivity rates of QFT-Plus and TSPOT were 5.9% (95%CI 3.0-11.3) and 3.7% (95%CI 1.6-8.4), respectively, with no significant difference. The concordance rate was 95.5% (kappa coefficient, 0.76). Age of 60 years and higher was related to the higher positivity rate in both QFT-Plus and TSPOT. The positivity rates of TB1 and TB2 were 5.1% (95%CI 2.5-10.2) and 5.9% (95%CI 3.0-11.2), respectively, with no significant difference. The concordance rate was 99.3% (kappa coefficient, 0.93). TB2 did not show a higher positivity rate compared with TB1. The estimated prevalence of LTBI by using the both IGRAs was 3.7-5.9% in renal transplant recipients. These results were equivalent to the IGRAs positivity rate in the general Japanese population, even under the condition of immunosuppressive therapy. In consideration of the higher risk of developing active TB from LTBI, we can use both IGRAs as acceptable tools for LTBI diagnosis in renal transplant recipients. CI - Copyright (c) 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. FAU - Igari, Hidetoshi AU - Igari H AD - Division of Infection Control, Chiba University Hospital, Chiba, Japan. Electronic address: igari_h@chiba-u.jp. FAU - Akutsu, Naotake AU - Akutsu N AD - Department of Surgery, National Hospital Organization Chiba-East Hospital, 673 Nitona-cho Chuo-ku, Chiba, 260-8712, Japan. Electronic address: nakutsu@cehpnet.com. FAU - Ishikawa, Satoru AU - Ishikawa S AD - Department of Respiratory Medicine, National Hospital Organization Chiba-East Hospital, 673 Nitona-cho Chuo-ku, Chiba, 260-8712, Japan. Electronic address: tetsu.is@gmail.com. FAU - Aoyama, Hiromichi AU - Aoyama H AD - Department of Surgery, National Hospital Organization Chiba-East Hospital, 673 Nitona-cho Chuo-ku, Chiba, 260-8712, Japan. Electronic address: a.hiromichi@cehpnet.com. FAU - Otsuki, Kazunori AU - Otsuki K AD - Department of Surgery, National Hospital Organization Chiba-East Hospital, 673 Nitona-cho Chuo-ku, Chiba, 260-8712, Japan. Electronic address: otsuki@cehpnet.com. FAU - Hasegawa, Masayuki AU - Hasegawa M AD - Department of Surgery, National Hospital Organization Chiba-East Hospital, 673 Nitona-cho Chuo-ku, Chiba, 260-8712, Japan. Electronic address: Clinic1159@yahoo.co.jp. FAU - Maruyama, Michihiro AU - Maruyama M AD - Department of Surgery, National Hospital Organization Chiba-East Hospital, 673 Nitona-cho Chuo-ku, Chiba, 260-8712, Japan. Electronic address: maruyama@cehpnet.com. FAU - Tsuyuzaki, Mizue AU - Tsuyuzaki M AD - Chiba Foundation for Health Promotion and Disease Prevention, 32-14 Shin-Minato Mihama-ku, Chiba, 261-0002, Japan. Electronic address: mi-tsuyuzaki@kenko-chiba.or.jp. FAU - Suzuki, Kiminori AU - Suzuki K AD - Chiba Foundation for Health Promotion and Disease Prevention, 32-14 Shin-Minato Mihama-ku, Chiba, 261-0002, Japan. Electronic address: kimi.suzuki@nifty.com. FAU - Saigo, Kenichi AU - Saigo K AD - Department of Surgery, National Hospital Organization Chiba-East Hospital, 673 Nitona-cho Chuo-ku, Chiba, 260-8712, Japan. Electronic address: k_saigo@cehpnet.com. LA - eng PT - Journal Article DEP - 20190321 PL - Netherlands TA - J Infect Chemother JT - Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy JID - 9608375 RN - 0 (Antigens, Bacterial) RN - 0 (Immunosuppressive Agents) SB - IM MH - Adult MH - Aged MH - Antigens, Bacterial/immunology MH - Cross-Sectional Studies MH - Female MH - Graft Rejection/immunology/prevention & control MH - Humans MH - Immunocompromised Host MH - Immunosuppressive Agents/administration & dosage/adverse effects MH - Interferon-gamma Release Tests/*statistics & numerical data MH - Japan/epidemiology MH - Kidney Transplantation/*adverse effects MH - Latent Tuberculosis/diagnosis/*epidemiology/microbiology MH - Male MH - Middle Aged MH - Mycobacterium tuberculosis/immunology/isolation & purification MH - Prevalence MH - Transplant Recipients/*statistics & numerical data MH - Young Adult OTO - NOTNLM OT - Latent tuberculosis infection OT - Lymphocyte subsets OT - QuantiFERON-TB gold plus OT - Renal transplantation OT - T-Spot.TB EDAT- 2019/03/25 06:00 MHDA- 2019/12/18 06:00 CRDT- 2019/03/26 06:00 PHST- 2018/11/21 00:00 [received] PHST- 2019/01/28 00:00 [revised] PHST- 2019/02/23 00:00 [accepted] PHST- 2019/03/25 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] PHST- 2019/03/26 06:00 [entrez] AID - S1341-321X(19)30061-3 [pii] AID - 10.1016/j.jiac.2019.02.018 [doi] PST - ppublish SO - J Infect Chemother. 2019 Jul;25(7):537-542. doi: 10.1016/j.jiac.2019.02.018. Epub 2019 Mar 21.